Armstrong World Industries, Inc. (AWI - Free Report) reported third-quarter 2018 results, wherein adjusted earnings of $1.11 per share missed the Zacks Consensus Estimate of $1.18 per share by 5.9%. However, the reported figure increased 23.4% from 90 cents per share in the prior-year quarter.
Net sales of $260.5 million surpassed the consensus mark of $250 million by 4.2%. Also, net sales increased 11.4% year over year, driven by greater average unit values ("AUV") in the Mineral Fiber segment from positive pricing and mix, as well as strong volume in the Architectural Specialties segment.
Notably, the company increased its full-year 2018 guidance for revenues and adjusted free cash flow, backed by strong organic growth in Architectural Specialties and higher AUV in Mineral Fiber. In fact, shares of Armstrong World increased more than 3% on Oct 30.
Armstrong World Industries, Inc. Price, Consensus and EPS Surprise
Cost of sales grew 13.6% to $162.6 million from $143.1 million in the prior-year quarter. Gross profit increased 7.8% to $97.9 million in the reported quarter from $90.8 million in the year-ago quarter.
Selling, general and administrative (SG&A) expenses increased 14.6% year over year to $35.3 million. The SG&A expenses were up mainly due to reconciliation of cost allocated to WAVE and higher incentive plan accrued in 2018.
Operating income grew 10% year over year to $81.3 million. Adjusted EBITDA improved 10.4% year over year to $100 million. Both the improvements were mainly backed by significant volume growth in the Architectural Specialties business, along with strong AUV and higher equity earnings from WAVE. However, higher SG&A expenses, along with increased input and manufacturing costs partially offset the positives.
Mineral Fiber (81.7% of total sales): Net sales in the segment were up 6.9% year over year to $212.8 million, backed by higher AUV, which was partially offset by lower volume.
Operating income dipped 1.8% to $71.8 million in the quarter due to higher depreciation related to the closed St. Helens plant, higher SG&A expenses, and greater manufacturing and input costs. Nevertheless, adjusted EBITDA grew 6.9% from the prior-year quarter to $88 million.
Architectural Specialties (18.3%): The segment’s sales increased 36.7% year over year to $47.7 million, owing to increased market penetration and new construction activity that contributed to strong volume growth.
Notably, the segment’s operating profit rose 46.8% year over year to $11.3 million. Also, adjusted EBITDA came in at $12 million, up 48.6% from the prior-year level.
Armstrong World reported cash and cash equivalents of $337 million at the end of the quarter compared with $116.5 million at the end of the prior-year quarter.
Net cash flow provided by operations was $159 million in the reported quarter compared with $104.9 million recorded in the year-earlier quarter.
For 2018, Armstrong World increased its net sales growth guidance to 8-9% from the prior guided range of 5-7%. While the company reaffirmed its view for adjusted EBITDA growth of more than 10%, it increased the midpoint of adjusted EPS range by 1 cent to $3.72.
However, adjusted free cash flow is now expected to grow 43-50%, up from prior expectation of 20-30%.
The company repurchased four million shares for $256 million in the first nine months of 2018. Since the inception of the repurchase program in 2016, Armstrong World repurchased 6.9 million shares for $300 million at an average share price of $55 per share.
Zacks Rank & Other Stocks to Consider
Armstrong World currently has a Zacks Rank #2 (Buy).
Other top-ranked stocks in the Zacks Construction sector include United Rentals, Inc. (URI - Free Report) , PGT Innovations, Inc. (PGTI - Free Report) and EMCOR Group, Inc. (EME - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
United Rentals, PGT Innovations and EMCOR’s 2018 earnings are expected to grow 52.7%, 77.1% and 18%, respectively.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>